Compare LyondellBasell Industries NV (LYB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Novo Nordisk A/S — how do they compare? LyondellBasell Industries NV trades at $63.73 (market cap $20.67B), while Novo Nordisk A/S trades at $45.85 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 10.1× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (6.44%). Which is the better fit depends on your goals.
| LYB | NVO | |
|---|---|---|
Market Cap | $20.67B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $63.98 |
52-Week Low | $42.28 | $35.29 |
Enterprise Value | $32.26B | $222.55B |
Dividend Yield | 6.44% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LyondellBasell Industries (LYB) trades at $62.65, up 5.13% today, reflecting positive momentum following a strong Q2 2026 earnings beat. The stock shows bullish technical signals with moving averages supporting an uptrend, while fundamentals reveal a mixed picture with declining revenue but improving quarterly EPS. Recent news highlights supply disruptions supporting margins and analyst upgrades after the earnings report.
The outlook is cautiously optimistic with a consensus price target of $70.56, suggesting upside potential. Key opportunities include operational leverage from cost cuts and favorable petrochemical supply dynamics, but risks persist from volatile commodity markets and negative net income margins. Institutional sentiment leans positive with recent stake increases.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
